ORIC
Price
$8.63
Change
+$0.32 (+3.85%)
Updated
Jun 17 closing price
Capitalization
893.36M
49 days until earnings call
Intraday BUY SELL Signals
VRDN
Price
$16.71
Change
+$0.73 (+4.57%)
Updated
Jun 17 closing price
Capitalization
1.85B
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ORIC vs VRDN

ORIC vs VRDN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ORIC vs. VRDN commentary
Jun 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORIC is a Hold and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 18, 2026
Stock price -- (ORIC: $8.63 vs. VRDN: $16.71)
Brand notoriety: ORIC and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORIC: 93% vs. VRDN: 84%
Market capitalization -- ORIC: $893.36M vs. VRDN: $1.85B
ORIC [@Biotechnology] is valued at $893.36M. VRDN’s [@Biotechnology] market capitalization is $1.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $116.49B to $0. The average market capitalization across the [@Biotechnology] industry is $1.95B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORIC’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • ORIC’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, both ORIC and VRDN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORIC’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 6 bullish TA indicator(s).

  • ORIC’s TA Score: 5 bullish, 2 bearish.
  • VRDN’s TA Score: 6 bullish, 1 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than ORIC.

Price Growth

ORIC (@Biotechnology) experienced а +14.46% price change this week, while VRDN (@Biotechnology) price change was +5.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.07%. For the same industry, the average monthly price growth was +6.59%, and the average quarterly price growth was +2219.87%.

Reported Earning Dates

ORIC is expected to report earnings on Aug 06, 2026.

VRDN is expected to report earnings on Aug 12, 2026.

Industries' Descriptions

@Biotechnology (+4.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.85B) has a higher market cap than ORIC($893M). ORIC YTD gains are higher at: 5.501 vs. VRDN (-46.305). ORIC has higher annual earnings (EBITDA): -148.72M vs. VRDN (-352.27M). VRDN has more cash in the bank: 762M vs. ORIC (282M). ORIC has less debt than VRDN: ORIC (3.3M) vs VRDN (51.2M). VRDN has higher revenues than ORIC: VRDN (70.9M) vs ORIC (0).
ORICVRDNORIC / VRDN
Capitalization893M1.85B48%
EBITDA-148.72M-352.27M42%
Gain YTD5.501-46.305-12%
P/E RatioN/AN/A-
Revenue070.9M-
Total Cash282M762M37%
Total Debt3.3M51.2M6%
FUNDAMENTALS RATINGS
ORIC vs VRDN: Fundamental Ratings
ORIC
VRDN
OUTLOOK RATING
1..100
3716
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6165
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORIC's Valuation (22) in the null industry is in the same range as VRDN (34) in the Biotechnology industry. This means that ORIC’s stock grew similarly to VRDN’s over the last 12 months.

ORIC's Profit vs Risk Rating (100) in the null industry is in the same range as VRDN (100) in the Biotechnology industry. This means that ORIC’s stock grew similarly to VRDN’s over the last 12 months.

ORIC's SMR Rating (100) in the null industry is in the same range as VRDN (100) in the Biotechnology industry. This means that ORIC’s stock grew similarly to VRDN’s over the last 12 months.

ORIC's Price Growth Rating (61) in the null industry is in the same range as VRDN (65) in the Biotechnology industry. This means that ORIC’s stock grew similarly to VRDN’s over the last 12 months.

ORIC's P/E Growth Rating (100) in the null industry is in the same range as VRDN (100) in the Biotechnology industry. This means that ORIC’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORICVRDN
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 6 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ORIC
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NRES33.20N/A
N/A
Xtrackers RREEF Global Natrl Res ETF
ARMY24.57-0.07
-0.27%
Tema ETF Trust
DYNB39.27-0.17
-0.43%
Hartford Dynamic Bond ETF
FDEC54.08-0.37
-0.68%
FT Vest US Equity Buffer ETF Dec
AMZY10.85-0.24
-2.16%
YieldMax AMZN Option Income Strategy ETF

ORIC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORIC has been loosely correlated with MLTX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ORIC jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORIC
1D Price
Change %
ORIC100%
+3.85%
MLTX - ORIC
40%
Loosely correlated
+1.00%
REPL - ORIC
37%
Loosely correlated
+13.90%
RKTO - ORIC
37%
Loosely correlated
-5.56%
WVE - ORIC
36%
Loosely correlated
+3.83%
RCUS - ORIC
35%
Loosely correlated
+2.42%
More